Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee.

genetically modified hematopoietic stem cell therapies immune reconstitution prophylaxis vaccination

Journal

Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309

Informations de publication

Date de publication:
20 Feb 2024
Historique:
received: 07 11 2023
revised: 12 02 2024
accepted: 12 02 2024
medline: 14 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: aheadofprint

Résumé

There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy.

Identifiants

DOI: 10.1016/j.jcyt.2024.02.005 PMID: 38483362
pubmed: 38483362
pii: S1465-3249(24)00052-5
doi: 10.1016/j.jcyt.2024.02.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : U01 HL163983
Pays : United States

Informations de copyright

Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Auteurs

Tami D John (TD)

Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA.

Gabriela Maron (G)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Allistair Abraham (A)

Center for Cancer and Immunology Research, CETI, Children's National Hospital, Washington, District of Columbia, USA.

Alice Bertaina (A)

Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA.

Senthil Velan Bhoopalan (SV)

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Alan Bidgoli (A)

Division of Blood and Marrow Transplantation, Children's Healthcare of Atlanta, Aflac Blood and Cancer Disorders Center, Emory University, Atlanta, Georgia, USA.

Carmem Bonfim (C)

Pediatric Blood and Marrow Transplantation Division and Pelé Pequeno Príncipe Research Institute, Hospital Pequeno Príncipe, Curitiba, Brazil.

Zane Coleman (Z)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Amy DeZern (A)

Bone Marrow Failure and MDS Program, John Hopkins Medicine, Baltimore, Maryland, USA.

Jingjing Li (J)

Graduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, Australia.

Chrystal Louis (C)

Zentalis Pharmaceuticals, New York, New York, USA.

Joseph Oved (J)

Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Mara Pavel-Dinu (M)

Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA.

Duncan Purtill (D)

Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.

Annalisa Ruggeri (A)

IRCCS Ospedale San Raffaele, Segrate, Milan, Italy.

Athena Russell (A)

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Robert Wynn (R)

Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Jaap Jan Boelens (JJ)

Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Susan Prockop (S)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.

Akshay Sharma (A)

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Electronic address: akshay.sharma@stjude.org.

Classifications MeSH